首页> 外文期刊>Frontiers in Neuroscience >Early Dyskinesias in Parkinson’s Disease Patients With Parkin Mutation: A Primary Corticostriatal Synaptopathy?
【24h】

Early Dyskinesias in Parkinson’s Disease Patients With Parkin Mutation: A Primary Corticostriatal Synaptopathy?

机译:帕金森氏症患者的帕金森病早期运动障碍:原发性皮质激素性突触病?

获取原文
       

摘要

Mutations in the PARKIN gene cause early-onset Parkinson’s disease (PD). Despite the high proportion of still missing phenotyping data in the literature devoted to early-onset PD, studies suggest that, as compared with late-onset PD, PARKIN patients show dystonia at onset and extremely dose-sensitive levodopa-induced dyskinesia (LID). What pathophysiological mechanisms underpin such early and atypical dyskinesia in patients with PARKIN mutations? Though the precise mechanisms underlying dystonia and LID are still unclear, evidence suggests that hyperkinetic disorders in PD are a behavioral expression of maladaptive functional and morphological changes at corticostriatal synapses induced by long-term dopamine (DA) depletion. However, since the dyskinesia in PARKIN patients can also be present at onset, other mechanisms beside the well-established DA depletion may play a role in the development of dyskinesia in these patients. Because cortical and striatal neurons express parkin protein, and parkin modulates the function of ionotropic glutamatergic receptors (iGluRs), an intriguing explanation may rest on the potential role of parkin in directly controlling the glutamatergic corticostriatal synapse transmission. We discuss the novel theory that loss of parkin function can dysregulate transmission at the corticostriatal synapses where they cause early maladaptive changes that co-occur with the changes stemming from DA loss. This hypothesis suggests an early striatal synaptopathy; it could lay the groundwork for pharmacological treatment of dyskinesias and LID in patients with PARKIN mutations.
机译:PARKIN基因的突变会导致帕金森氏病(PD)早发。尽管有关早发性PD的文献中仍然缺少大量的表型数据,但研究表明,与晚发性PD相比,PARKIN患者起病时出现肌张力障碍,并且对左旋多巴引起的剂量敏感性极强(LID)。 PARKIN突变患者早期和非典型运动障碍的病理生理机制是什么?尽管肌张力障碍和LID的确切机制尚不清楚,但证据表明PD的运动亢进是长期多巴胺(DA)消耗引起的皮质上突触突触不良的功能和形态变化的行为表达。但是,由于PARKIN患者的运动障碍也可以在发作时出现,因此,除了已确立的DA耗竭外,其他机制也可能在这些患者的运动障碍发展中起作用。因为皮层和纹状体神经元表达帕金蛋白,而帕金调节离子型谷氨酸能受体(iGluRs)的功能,所以一个有趣的解释可能是帕金在直接控制谷氨酸能皮质口突触传递中的潜在作用。我们讨论了一种新的理论,即帕金功能的丧失会导致皮质口突触的传递失调,在皮质突触中它们会引起早期适应不良的变化,而这种不良反应与DA丧失引起的变化同时发生。该假说表明是早期纹状体突触病。它可以为PARKIN突变患者的运动障碍和LID的药物治疗奠定基础。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号